CD274 and hepatocellular carcinoma: Therapeutically blocking T‐cell co‐suppressor molecules, including cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4), programmed cell death Receptor 1 (PD‐1), or its ligand (PD‐L1), has shown durable antitumor responses and long‐term remission in various solid tumors.[4] Despite promising results of immunotherapies, variable patient responses and the lack of validated predictive biomarkers highlight the urgent need for reliable prognostic tools in HCC treatment.